Accuray Incorporated ( (ARAY) ) has released its Q4 earnings. Here is a breakdown of the information Accuray Incorporated presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Accuray Incorporated is a company specializing in radiation therapy solutions, focusing on innovative treatments for complex and common cases in the oncology and neuro-radiosurgery sectors. Headquartered in Madison, Wisconsin, Accuray operates globally, partnering with clinicians and administrators to enhance patient care.
Accuray’s latest financial report for the fourth quarter and fiscal year 2025 reveals a mixed performance with a slight decline in quarterly revenue but an overall annual revenue increase. The company successfully completed a debt refinancing, which positions it well for future growth, and provided guidance for fiscal year 2026.
For the fourth quarter, Accuray reported a net revenue of $127.5 million, a 5% decrease from the previous year, and a net income of $1.1 million, down from $3.4 million. The adjusted EBITDA for the quarter was $9.4 million, slightly lower than the previous year’s $10.1 million. However, the fiscal year 2025 results showed a 3% increase in net revenue to $458.5 million, with a reduced net loss of $1.6 million compared to $15.5 million the previous year. The adjusted EBITDA for the year improved significantly to $28.3 million from $19.7 million.
Accuray’s management highlighted the company’s resilience in navigating macroeconomic challenges and its strategic focus on innovation and service growth. The successful debt refinancing is expected to support the company’s long-term objectives, and the introduction of fiscal year 2026 guidance indicates a positive outlook with anticipated revenue growth and improved adjusted EBITDA.
Looking ahead, Accuray is projecting fiscal year 2026 net revenue between $471 million and $485 million, with adjusted EBITDA expected to range from $31 million to $35 million. The company remains committed to advancing its core strategies and expanding its global business, despite potential market and economic uncertainties.